Oncolytics Biotech (ONCY) Capital Expenditures (2009 - 2024)
Oncolytics Biotech's (ONCY) quarterly Capital Expenditures came in at -$4295.1 in Q4 2024, down 94.91% year-on-year from -$84417.1 in Q1 2024, and up 81.69% on a QoQ basis from -$23457.7 in Q3 2024.
Oncolytics Biotech (ONCY) Capital Expenditures (2009 - 2024) Analysis & Trends
Oncolytics Biotech (ONCY) has 16 years of Capital Expenditures data on file, last reported at -$4295.1 in Q4 2024.
- On a quarterly basis, Capital Expenditures fell 94.91% year-over-year to -$4295.1 in Q4 2024; TTM through Dec 2024 was -$175216.8, a 2868.73% decrease from a year earlier, with the FY2025 full-year figure at $6000.0, down 96.55% from the prior year.
- Capital Expenditures for Q4 2024 stood at -$4295.1, up from -$23457.7 in the prior quarter.
- Over the last five years, Capital Expenditures for ONCY reached as high as $394475.3 in Q4 2021 and fell as low as -$162566.3 in Q3 2021.
- Historically, Capital Expenditures has averaged -$1171.6 across 5 years, with a median of -$6900.7 in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 168513.99% in 2021 and fell as far as 1292.6% in 2021.
- Year by year, Capital Expenditures stood at $233.95 in 2020, then surged by 168513.99% to $394475.3 in 2021, then sank by 99.81% to $736.7 in 2022, then tumbled by 399.12% to -$2203.6 in 2023, then tumbled by 94.91% to -$4295.1 in 2024.
- Per Business Quant data, the three most recent Capital Expenditures figures were -$4295.1 in Q4 2024, -$23457.7 in Q3 2024, and -$113326.8 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Oncolytics Biotech | 372.40 Mn | 372.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -4,295.09 |
| Dec 31, 2024 | -4,295.09 |
| Sep 30, 2024 | -23,457.71 |
| Sep 30, 2024 | -23,457.71 |
| Jun 30, 2024 | -113,326.78 |
| Jun 30, 2024 | -113,326.78 |
| Mar 31, 2024 | -34,137.21 |
| Mar 31, 2024 | -34,137.21 |
| Dec 31, 2023 | -2,203.61 |
| Dec 31, 2023 | -2,203.61 |
| Mar 31, 2023 | -3,698.48 |
| Mar 31, 2023 | -3,698.48 |
| Dec 31, 2022 | 736.70 |
| Dec 31, 2022 | 736.70 |
| Sep 30, 2022 | -6,900.72 |
| Sep 30, 2022 | -6,900.72 |
| Jun 30, 2022 | -9,133.65 |
| Jun 30, 2022 | -9,133.65 |
| Mar 31, 2022 | -28,421.11 |
| Mar 31, 2022 | -28,421.11 |